Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Osteoporosis
•
Bisphosphonate
Do you use bisphosphonates in combination with SERMs in female patients with progressive decline in bone density despite being on a SERM for post-menopausal symptoms other than osteoporosis?
Related Questions
Is there any contraindication for use of Invisalign teeth aligners in patients undergoing treatment for osteoporosis?
For postmenopausal osteoporosis, would you give denosumab after a course of teriparatide and romosozumab to women who had an atypical femoral fracture while on bisphosphonate therapy a few years earlier?
Given the risk of hypocalcemia in dialysis dependent patients treated with denosumab, what is the best method of treatment for osteoporosis for these patients, and should we be transitioning to a different agent?
Have you been able to safely use other bisphosphonates in patients who developed an allergic reaction (angioedema) to fosamax?
What is your approach to managing osteoporosis in patients with end stage kidney disease?
How frequently do you monitor for hypocalcemia in patients on romosozumab?
Are there any concerns with using denosumab in a patient with chronic hepatitis B infection on antiviral therapy?
Would you have concerns about combining romosuzumab and IVIG in a patient with dermatomyositis and osteoporosis?
Is there a PTH elevation above which you would be hesitant to use an anabolic agent in a patient with osteoporosis and CKD stage 4 or 5?
How do you determine osteoporosis treatment response when patients have discrepant DEXA scan results during monitoring (eg improved BMD of the hip and spine but worsening BMD of the femoral neck)?
